Erick Lucera

CIK: 0001697616

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)5 (12.2%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)21 (51.2%)

Compensation grants

Other (G, F, J, C, D, …)15 (36.6%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (4)

DYN

Dyne Therapeutics, Inc.

Officer

SABS

SAB Biotherapeutics, Inc.

Director

XAIR

Beyond Air, Inc.

Director

EDIT

Editas Medicine, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (41 total)

DYN
Dyne Therapeutics, Inc.
Aug 13, 2026
Sale(S)
Direct
1.8K shares at avg. $26.28$47K
DYN
Dyne Therapeutics, Inc.
Jun 25, 2026
Sale(S)
Direct
2.4K shares at avg. $20.37$48K
DYN
Dyne Therapeutics, Inc.
May 13, 2026
Sale(S)
Direct
1.4K shares at avg. $18.36$27K
DYN
Dyne Therapeutics, Inc.
Apr 1, 2026
Sale(S)
Direct
5.7K shares at avg. $18.64$107K
DYN
Dyne Therapeutics, Inc.
Feb 12, 2026
Award(A)
Direct
65K shares-
SABS
SAB Biotherapeutics, Inc.
Dec 16, 2025
Award(A)
Stock option (right to buy)
Direct
150K shares-
XAIR
Beyond Air, Inc.
Nov 4, 2025
Disposition(D)
Stock Options (Right to buy)
Direct
1.3K shares-
XAIR
Beyond Air, Inc.
Nov 4, 2025
Disposition(D)
Stock Options (Right to buy)
Direct
3.8K shares-
XAIR
Beyond Air, Inc.
Nov 4, 2025
Award(A)
Stock Options (Right to buy)
Direct
1K shares-
XAIR
Beyond Air, Inc.
Nov 4, 2025
Award(A)
Stock Options (Right to buy)
Direct
1.3K shares-
XAIR
Beyond Air, Inc.
Nov 4, 2025
Award(A)
Stock Options (Right to buy)
Direct
3.8K shares-
XAIR
Beyond Air, Inc.
Nov 4, 2025
Disposition(D)
Stock Options (Right to buy)
Direct
2.3K shares-
XAIR
Beyond Air, Inc.
Nov 4, 2025
Award(A)
Stock Options (Right to buy)
Direct
2.3K shares-
XAIR
Beyond Air, Inc.
Nov 4, 2025
Disposition(D)
Stock Options (Right to buy)
Direct
2K shares-
XAIR
Beyond Air, Inc.
Nov 4, 2025
Award(A)
Stock Options (Right to buy)
Direct
2K shares-
XAIR
Beyond Air, Inc.
Nov 4, 2025
Disposition(D)
Stock Options (Right to buy)
Direct
1.5K shares-
XAIR
Beyond Air, Inc.
Nov 4, 2025
Award(A)
Stock Options (Right to buy)
Direct
1.5K shares-
XAIR
Beyond Air, Inc.
Nov 4, 2025
Disposition(D)
Stock Options (Right to buy)
Direct
1.3K shares-
XAIR
Beyond Air, Inc.
Nov 4, 2025
Award(A)
Stock Options (Right to buy)
Direct
1.3K shares-
XAIR
Beyond Air, Inc.
Nov 4, 2025
Disposition(D)
Stock Options (Right to buy)
Direct
1.3K shares-
XAIR
Beyond Air, Inc.
Nov 4, 2025
Award(A)
Stock Options (Right to buy)
Direct
1.3K shares-
XAIR
Beyond Air, Inc.
Nov 4, 2025
Disposition(D)
Stock Options (Right to buy)
Direct
1K shares-
DYN
Dyne Therapeutics, Inc.
Mar 31, 2025
Award(A)
Direct
66.1K shares-
XAIR
Beyond Air, Inc.
Mar 26, 2025
Award(A)
Stock Options (Right to buy)
Direct
75K shares-
EDIT
Editas Medicine, Inc.
Mar 8, 2025
Award(A)
Stock Option (right to buy)
Direct
70K shares-

		Type	Shares	Price		Ownership
Aug 13, 2026	DYN Dyne Therapeutics, Inc.	Sale(S)	1,797	$26.28	$47,225	Direct
Jun 25, 2026	DYN Dyne Therapeutics, Inc.	Sale(S)	2,362	$20.37	$48,114	Direct
May 13, 2026	DYN Dyne Therapeutics, Inc.	Sale(S)	1,448	$18.36	$26,585	Direct
Apr 1, 2026	DYN Dyne Therapeutics, Inc.	Sale(S)	5,727	$18.64	$106,751	Direct
Feb 12, 2026	DYN Dyne Therapeutics, Inc.	Award(A)	65,000	-	$0	Direct
Dec 16, 2025	SABS SAB Biotherapeutics, Inc.	Award(A) Stock option (right to buy)	150,000	-	-	Direct
Nov 4, 2025	XAIR Beyond Air, Inc.	Disposition(D) Stock Options (Right to buy)	1,250	-	-	Direct
Nov 4, 2025	XAIR Beyond Air, Inc.	Disposition(D) Stock Options (Right to buy)	3,750	-	-	Direct
Nov 4, 2025	XAIR Beyond Air, Inc.	Award(A) Stock Options (Right to buy)	1,000	-	-	Direct
Nov 4, 2025	XAIR Beyond Air, Inc.	Award(A) Stock Options (Right to buy)	1,250	-	-	Direct
Nov 4, 2025	XAIR Beyond Air, Inc.	Award(A) Stock Options (Right to buy)	3,750	-	-	Direct
Nov 4, 2025	XAIR Beyond Air, Inc.	Disposition(D) Stock Options (Right to buy)	2,250	-	-	Direct
Nov 4, 2025	XAIR Beyond Air, Inc.	Award(A) Stock Options (Right to buy)	2,250	-	-	Direct
Nov 4, 2025	XAIR Beyond Air, Inc.	Disposition(D) Stock Options (Right to buy)	2,000	-	-	Direct
Nov 4, 2025	XAIR Beyond Air, Inc.	Award(A) Stock Options (Right to buy)	2,000	-	-	Direct
Nov 4, 2025	XAIR Beyond Air, Inc.	Disposition(D) Stock Options (Right to buy)	1,500	-	-	Direct
Nov 4, 2025	XAIR Beyond Air, Inc.	Award(A) Stock Options (Right to buy)	1,500	-	-	Direct
Nov 4, 2025	XAIR Beyond Air, Inc.	Disposition(D) Stock Options (Right to buy)	1,250	-	-	Direct
Nov 4, 2025	XAIR Beyond Air, Inc.	Award(A) Stock Options (Right to buy)	1,250	-	-	Direct
Nov 4, 2025	XAIR Beyond Air, Inc.	Disposition(D) Stock Options (Right to buy)	1,250	-	-	Direct
Nov 4, 2025	XAIR Beyond Air, Inc.	Award(A) Stock Options (Right to buy)	1,250	-	-	Direct
Nov 4, 2025	XAIR Beyond Air, Inc.	Disposition(D) Stock Options (Right to buy)	1,000	-	-	Direct
Mar 31, 2025	DYN Dyne Therapeutics, Inc.	Award(A)	66,100	-	-	Direct
Mar 26, 2025	XAIR Beyond Air, Inc.	Award(A) Stock Options (Right to buy)	75,000	-	-	Direct
Mar 8, 2025	EDIT Editas Medicine, Inc.	Award(A) Stock Option (right to buy)	70,000	-	-	Direct

1-25 of 41 transactions

About Lucera Erick

Lucera Erick (SEC CIK 0001697616) files insider reports with the SEC as Chief Financial Officer of Dyne Therapeutics, Inc. (DYN), Director of SAB Biotherapeutics, Inc. (SABS) and Director of Beyond Air, Inc. (XAIR). Signal8 also holds filings tied to 1 other company.

Signal8 holds 13 ownership filings by Lucera Erick (1 Form 3, 12 Form 4), filed between Nov 26, 2024 and Aug 17, 2026. Those filings report 41 transactions, from Nov 22, 2024 to Aug 13, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Lucera Erick's filings is in WALTHAM, MA.

Recent filings by Lucera Erick

Aug 13, 2026: Open-market sale of DYN shares (Form 4, code S).
Jun 25, 2026: Open-market sale of DYN shares (Form 4, code S).
May 13, 2026: Open-market sale of DYN shares (Form 4, code S).
Apr 1, 2026: Open-market sale of DYN shares (Form 4, code S).
Feb 12, 2026: Grant or award of DYN shares (Form 4, code A).

Other insiders filing for Dyne Therapeutics, Inc. (DYN)

Kerr Douglas, Head of R&D and CMO
Posner Brian S, Director
Friedl-Naderer Johanna, Chief Commercial Officer
Cox John, CEO & President
Rhodes Jason P, Director
Kersten Dirk, Director

How to read Form 4 transaction codes